Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Thrombocytopenic Purpura
Conditions
Idiopathic Thrombocytopenic Purpura
Trial Timeline
May 1, 2007 → Oct 1, 2009
NCT ID
NCT00625443About Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets) is a phase 2 stage product being developed by Eisai for Idiopathic Thrombocytopenic Purpura. The current trial status is completed. This product is registered under clinical trial identifier NCT00625443. Target conditions include Idiopathic Thrombocytopenic Purpura.
What happened to similar drugs?
20 of 20 similar drugs in Idiopathic Thrombocytopenic Purpura were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00625443 | Phase 2 | Completed |
Competing Products
20 competing products in Idiopathic Thrombocytopenic Purpura